2024-10-29 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis:

**1. Performance vs. S&P 500:**

Eli Lilly and Co (LLY) is a global pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products, including diabetes treatments, cancer therapies, and immunology medications. 

LLY has significantly outperformed the S&P 500 (VOO) in the past period. The cumulative return for LLY is 860.77%, while the S&P 500's is 136.36%, resulting in a difference of 724.41. This places LLY at the 89.97th percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movements:**

* **Last Closing Price:** $895.59 (Last-market: $896.31)
* **5-Day Moving Average:** $898.40
* **20-Day Moving Average:** $905.77
* **60-Day Moving Average:** $909.58

The stock price is currently trading below its 5-day, 20-day, and 60-day moving averages, suggesting a potential downward trend. 

**3. Technical Indicators:**

* **RSI:** 40.63 - This indicates a neutral to slightly oversold position for the stock, but not a strong sell signal.
* **PPO:** -0.24 - A negative PPO value suggests a potential downtrend, but the magnitude is relatively small.
* **Delta_Previous_Relative_Divergence:** 0.51 (+) - This shows a short-term upward trend in the stock's relative strength. 
* **Expected Return:** 96.95% - This suggests that LLY is expected to outperform the S&P 500 by 96.95% over the long term (2 years or more) for investors employing a long-term accumulation strategy.

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-08-08 | 3.29 | $11.30 B      |
| 2024-04-30 | 2.49 | $8.77 B       |
| 2023-11-02 | -0.06 | $9.50 B       |
| 2023-08-08 | 1.96 | $8.31 B       |
| 2024-08-08 | 1.96 | $8.31 B       |

The most recent earnings for the quarter ending August 8, 2024, showed an EPS of $3.29, exceeding analysts' estimates by 11 cents. Revenue came in at $11.30 billion, exceeding expectations as well. This strong performance indicates continued growth and robust demand for LLY's products.

**5. Financial Trends Analysis:**

| Item               | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|--------------------|---------------|---------------|---------------|
| Revenue            | $11.30B         | $8.77B          | $9.35B          | 
| Gross Profit       | $9.13B          | $7.09B          | $7.57B          | 
| Gross Margin %     | 80.80%          | 80.91%          | 80.88%          | 
| Operating Income   | $4.42B          | $2.74B          | $3.54B          | 
| Operating Margin % | 39.09%          | 31.20%          | 37.85%          | 
| Net Income         | $2.97B          | $2.24B          | $2.19B          | 
| Net Margin %       | 26.25%          | 25.58%          | 23.41%          | 
| EPS                | $3.30           | $2.49           | $2.43           | 
| ROE %              | 21.88%          | 17.51%          | 20.33%          | 
| Total Assets       | $71.87B         | $63.94B         | $64.01B         | 
| Total Liabilities  | $58.24B         | $51.05B         | $53.14B         | 
| Total Equity       | $13.56B         | $12.81B         | $10.77B         | 
| Operating Cash Flow | $1.47B          | $1.17B          | $-0.31B         | 
| Capital Expenditure | $-1.40B         | $-1.08B         | $-1.65B         | 

LLY's financial trends show consistent revenue growth, strong profitability with healthy margins, and positive earnings. The company's Return on Equity (ROE) is also commendable, demonstrating efficient utilization of shareholder capital.

**6. News and Recent Issues:**

According to recent earnings calls, LLY is experiencing strong demand for its products, especially in its diabetes and oncology segments.  The company is investing heavily in research and development to expand its pipeline and maintain a competitive edge in the pharmaceutical market.

**7. Analyst Opinions and Performance Highlights:**

* **FINBOLD:** LLY has a positive outlook from analysts, with a consensus price target of $108.33, suggesting a potential upside of ~20%. 
* **Shaacknews:**  Recent earnings reports were well received, highlighting strong growth in the key segments.  Analysts remain optimistic about LLY's future performance.

**8. Overall Analysis:**

Overall, Eli Lilly and Co (LLY) appears to be a strong performer with a solid track record of growth and profitability. It has significantly outperformed the S&P 500, demonstrating a strong long-term investment potential.  While the stock price is currently experiencing a slight downward trend, technical indicators suggest a potential short-term upward swing. The company's strong earnings and positive analyst sentiment reinforce its bullish outlook. 

**9. Recommendations:**

For long-term investors, LLY is a compelling investment opportunity with a high potential for growth. The company's commitment to innovation, strong financial performance, and optimistic outlook from analysts indicate a bright future. Investors should monitor the stock's price movements and technical indicators to identify potential entry and exit points. 

**Note:** This analysis is based on publicly available information and should not be considered financial advice. It is crucial to conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions.